New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo) after bladder cancer surgery reduced their overall risk ...
Jun 4, 2021
0
12
(HealthDay)—For patients with stage II pancreatic cancer, attempted surgery with margin-positive resection may offer survival benefit over chemotherapy alone, according to a study published online March 26 in the Journal ...
Apr 22, 2021
0
2
Liquid biopsy is likely to play an increasing role in identifying patients with colorectal cancer (CRC) who are likely to relapse after surgery, and has potential for optimising treatment for individual patients, according ...
Sep 28, 2019
0
4
(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...
Feb 13, 2019
0
2
(HealthDay)—Pembrolizumab is associated with significantly longer recurrence-free survival than placebo as adjuvant therapy for high-risk stage III melanoma, according to a study published online April 15 in the New England ...
Apr 16, 2018
0
2
Some stage III colon cancer patients can cut in half the number of chemotherapy treatments they receive after surgery, significantly reducing the costs, treatment time, and long-term toxic effects of chemotherapy, according ...
Mar 28, 2018
0
5
Results of an analysis from the University of Cincinnati (UC) College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase ...
Mar 25, 2018
0
8
Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today ...
Sep 11, 2017
0
0
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 ...
Oct 8, 2016
0
5
(HealthDay)—The American Society of Clinical Oncology (ASCO) has endorsed the Cancer Care Ontario (CCO) recommendations on the role of patient and disease factors in selecting adjuvant therapy for early-stage breast cancer, ...
Mar 23, 2016
0
0
